CytomX Therapeutics, Inc. (CTMX) Operating Margin
- Operating margin · 12 months: Value -476.17%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -476.17% | Operating income / revenue. Period ending 2026-06-30. $-87.15M ÷ $18.30M × 100 ≈ -476.17% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -87.15M USD | Operating Income (Loss) |
| Revenue | 18.30M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 73.38M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-87.15M | $18.30M | (m) | $73.38M | (m) | -476.17% |
| 2026-03-31 | $-64.66M | $35.54M | (m) | $69.10M | (m) | -181.92% |
| 2025-12-31 | $-22.36M | $76.20M | (m) | $68.73M | (m) | -29.35% |
| 2025-09-30 | $23.25M | $113.63M | (m) | $62.28M | (m) | 20.46% |
| 2025-06-30 | $43.13M | $141.10M | (m) | $68.35M | (m) | 30.56% |
| 2025-03-31 | $35.96M | $147.56M | (m) | $80.20M | (m) | 24.37% |
| 2024-12-31 | $25.00M | $138.10M | (m) | $83.38M | (m) | 18.10% |
| 2024-09-30 | $6.71M | $126.62M | (m) | $87.98M | (m) | 5.30% |
| 2024-06-30 | $5.72M | $119.57M | (m) | $83.06M | (m) | 4.79% |
| 2024-03-31 | $10.83M | $119.18M | (m) | $78.56M | (m) | 9.08% |
| 2023-12-31 | $-6.48M | $101.21M | (m) | $77.68M | (m) | -6.41% |
| 2023-09-30 | $-15.39M | $94.73M | (m) | $77.86M | (m) | -16.24% |
| 2023-06-30 | $-48.22M | $79.49M | (m) | $91.78M | (m) | -60.66% |
| 2023-03-31 | $-74.93M | $67.62M | (m) | $102.27M | (m) | -110.80% |
| 2022-12-31 | $-101.33M | $53.16M | (m) | $111.65M | (m) | -190.61% |
| 2022-09-30 | $-98.96M | $71.94M | (m) | $128.66M | (m) | -137.55% |
| 2022-06-30 | $-97.66M | $72.62M | (m) | $127.44M | (m) | -134.48% |
| 2022-03-31 | $-92.12M | $70.74M | (m) | $122.38M | (m) | -130.23% |
| 2021-12-31 | $-83.78M | $69.57M | (m) | $114.19M | (m) | -120.42% |
| 2021-09-30 | $-72.25M | $66.22M | (m) | $99.62M | (m) | -109.11% |
| 2021-06-30 | $-64.51M | $66.42M | (m) | $94.53M | (m) | -97.12% |
| 2021-03-31 | $-61.44M | $66.74M | (m) | $92.49M | (m) | -92.06% |
| 2020-12-31 | $-48.60M | $100.36M | (m) | $112.94M | (m) | -48.43% |
| 2020-09-30 | $-71.20M | $92.27M | (m) | $127.37M | (m) | -77.17% |
| 2020-06-30 | $-82.03M | $85.19M | (m) | $131.29M | (m) | -96.29% |
| 2020-03-31 | $-97.12M | $77.60M | (m) | $138.06M | (m) | -125.16% |
| 2019-12-31 | $-110.89M | $57.49M | (m) | $131.62M | (m) | -192.90% |
| 2019-09-30 | $-99.33M | $60.68M | (m) | $123.48M | (m) | -163.69% |
| 2019-06-30 | $-96.78M | $62.48M | (m) | $123.07M | (m) | -154.91% |
| 2019-03-31 | $-78.81M | $74.80M | (m) | $117.78M | (m) | -105.36% |
| 2018-12-31 | $-77.87M | $59.50M | (m) | $103.87M | (m) | -130.88% |
| 2018-09-30 | $-53.31M | $75.10M | (m) | $96.26M | (m) | -70.98% |
| 2018-06-30 | $-41.16M | $86.74M | (m) | $97.64M | (m) | -47.45% |
| 2018-03-31 | $-53.27M | $74.15M | (m) | $100.16M | (m) | -71.84% |
| 2017-12-31 | $-46.26M | $71.62M | (m) | $92.28M | (m) | -64.59% |
| 2017-09-30 | $-59.24M | $50.82M | (m) | $86.92M | (m) | -116.57% |
| 2017-06-30 | $-63.13M | $30.13M | (m) | $71.34M | (m) | -209.53% |
| 2017-03-31 | $-52.02M | $24.47M | (m) | $55.97M | (m) | -212.55% |
| 2016-12-31 | $-59.59M | $15.04M | (m) | $54.76M | (m) | -396.10% |
| 2016-09-30 | $-56.88M | $10.76M | (m) | $48.91M | (m) | -528.67% |
| 2016-06-30 | $-53.23M | $9.24M | (m) | $44.73M | (m) | -575.87% |
| 2016-03-31 | $-44.52M | $8.19M | (m) | $37.06M | (m) | -543.35% |
| 2015-12-31 | $-33.20M | $7.71M | (m) | $28.36M | (m) | -430.54% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $7.56M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $6.18M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-29.77M | $5.08M | (m) | $28.30M | (m) | -586.27% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-14.96M | $888.00K | (m) | $10.89M | (m) | -1684.23% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |